Benitec Biopharma (BNTC) Cash from Investing Activities (2019 - 2025)

Benitec Biopharma has reported Cash from Investing Activities over the past 6 years, most recently at -$11000.0 for Q4 2025.

  • Quarterly results put Cash from Investing Activities at -$11000.0 for Q4 2025, up 8.33% from a year ago — trailing twelve months through Dec 2025 was -$17000.0 (up 91.1% YoY), and the annual figure for FY2025 was -$18000.0, up 89.94%.
  • Cash from Investing Activities reached -$11000.0 in Q4 2025 per BNTC's latest filing, down from -$6000.0 in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $141000.0 in Q2 2021 and bottomed at -$179000.0 in Q1 2024.
  • Median Cash from Investing Activities over the past 4 years was -$12000.0 (2024), compared with a mean of -$13571.4.
  • The largest annual shift saw Cash from Investing Activities surged 1184.62% in 2021 before it crashed 109.22% in 2022.
  • Over 4 years, Cash from Investing Activities stood at $141000.0 in 2021, then plummeted by 109.22% to -$13000.0 in 2022, then grew by 7.69% to -$12000.0 in 2024, then grew by 8.33% to -$11000.0 in 2025.
  • Business Quant data shows Cash from Investing Activities for BNTC at -$11000.0 in Q4 2025, -$6000.0 in Q1 2025, and -$12000.0 in Q4 2024.